Cardiosphere derived cell population and methods of use

Patent metadata

Field	Value
Publication number	US-9492484-B2
Application number	US-201314038571-A
Country	US
Kind code	B2
Filing date	Sep 26, 2013
Priority date	Sep 27, 2012
Publication date	Nov 15, 2016
Grant date	Nov 15, 2016

Abstract

Provided herein are compositions and methods for isolating and culturing cardiac progenitor cells, and for improved transplantation.

First claim

What is claimed is:

1. A method of performing matrix-assisted cell transplantation (MACT) comprising:
contacting mammalian cells with matrix components comprising macromers and a crosslinker, wherein the crosslinker comprises a peptide that comprises CQPQGLAKC (SEQ ID NO:8); and
administering the matrix components and cells to a mammalian subject to allow for in situ crosslinking of the matrix components thereby forming a matrix within the mammalian subject.

2. The method of claim 1 , wherein the administering comprises injection.

3. The method of claim 1 , wherein the matrix is conjugated to cysteine-terminating peptides.

4. The method of claim 1 , wherein the mammalian subject has an injured heart.

5. The method of claim 4 , wherein the administering is to the injured heart.

6. The method of claim 1 , wherein the mammalian subject has an infarcted heart.

7. The method of claim 6 , wherein the administering is to the infarcted heart.

8. The method of claim 1 , wherein the mammalian subject has an ischemic heart.

9. The method of claim 8 , wherein the administering is to the ischemic heart.

10. The method of claim 1 , wherein the mammalian subject has damaged blood vessels.

11. The method of claim 10 , wherein the administering is to the site of the damaged blood vessels.

12. The method of claim 1 , wherein the mammalian subject is a human subject.

13. The method of claim 1 , wherein the cells are autologous to the subject.

14. The method of claim 1 , wherein the cells are allogeneic to the subject.

15. The method of claim 1 , wherein the matrix further comprises a growth factor.

16. The method of claim 1 , wherein the matrix and proliferated and differentiated cells further comprise a growth factor or an angiogenesis promoting factor.

17. The method of claim 10 , wherein the damaged blood vessels are due to a disease or condition selected from the group consisting of peripheral arterial disease, critical limb ischemia, chronic wounds and stroke.

18. The method of claim 1 , wherein the macromers comprise hyaluronic acid (HyA).

19. The method of claim 1 , wherein the macromers comprise acrylayted hyaluronic acid (AcHyA).

20. The method of claim 1 , wherein the cells are progenitor cells.

21. The method of claim 20 , wherein the progenitor cells are Sca-1 + CD45 − cells.

22. The method of claim 21 , wherein the progenitor cells are obtained from cardiospheres from heart tissue.

23. The method of claim 22 , wherein the heart tissue is human heart tissue.

24. The method of claim 20 , wherein the progenitor cells are cardiac progenitor cells and at least 3% of the cardiac progenitor cells express Isl1.

25. The method of claim 24 , wherein at least 10% of the cardiac progenitor cells express Isl1.

26. The method of claim 20 , wherein the progenitor cells express a cell surface marker selected from the group consisting of c-kit, CD31, CD44, CD80, CD90, CD105, CD133, CD34, Sca-1, and CD45.

Assignees

• Univ California
• Univ California

Inventors

• Yeghiazarians Yerem
• Ye Jianqin
• Boyle Andrew
• Healy Kevin E
• Jha Amit K

Classifications

• A61K35/34 Primary

  Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44) · CPC title

• C12N2533/80

  Hyaluronan · CPC title

• C12N5/0657

  Cardiomyocytes; Heart cells · CPC title